Showing papers on "Solid lipid nanoparticle published in 2001"

Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions

Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

Encapsulation of retinoids in solid lipid nanoparticles (SLN)

Abstract: SLN have been suggested for a broad range of applications, such as intravenous injection, peroral, or dermal administration. The incorporation of the drug in the core of the SLN has to be ensured for these applications, but the inclusion of drugs in SLN is poorly understood. This study is a contribution to further describe the inclusion properties of colloidal lipids and to propose incorporation mechanisms. Besides the well known methods to investigate entrapment of actives in nanoparticles such as DSC or microscopy, the present study focussed on yet a different approach. Based on the different chemical stability of retinoids in water and in a lipid phase, a method to derive information on the distribution of the drug between SLN-lipid and the water phase was established. Comparing different lipids, glyceryl behenate gave superior entrapment compared to tripalmitate, cetyl palmitate and solid paraffin. Comparing three different drugs, entrapment increased with decreasing polarity of the molecule (tretinoin < retinol < retinyl palmitate). The encapsulation efficacy was successfully enhanced by formulating SLN from mixtures of liquid and solid lipids. These particles were solid and provided better protection of the sensitive drugs than an emulsion. X-ray investigations revealed that good encapsulation correlated with a low degree of crystallinity and lattice defects. With highly ordered crystals, as in the case of cetyl palmitate, drug expulsion from the carrier was more pronounced.

Investigations on the occlusive properties of solid lipid nanoparticles (SLN).

Abstract: Skin hydration can be influenced to a great extent by occlusive compounds. Conventional highly occlusive compounds tend to have an unacceptable appearance. Therefore, the development of innovative occlusive topicals is an essential issue regarding the formulation of cosmetic and pharmaceutical preparations. Solid lipid nanoparticles (SLN) represent a novel carrier system for controlled release of topical cosmetic and pharmaceutical compounds. In addition to their controlled release characteristics, it has been found that SLN have an occlusive effect. The extent of the occlusive effect depends on various factors such as particle size, applied sample volume, lipid concentration, and crystallinity of the lipid matrix. These factors have been investigated in detail by an in vitro test, and the obtained data give insight into their importance.

A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles

Abstract: Solid lipid nanoparticles (SLN) have been introduced as a novel carrier system for drugs and cosmetics. It has been found that SLN possess characteristics of physical UV-blockers on their own, thus offering the possibility of developing a more effective sunscreen system with reduced side-effects. Incorporation of the chemical sunscreen tocopherol acetate into SLN prevents chemical degradation and increases the UV-blocking capacity. Aqueous SLN dispersions were produced and incorporated into gels, followed by particle size examination, stability testing upon storage and thermoanalytical examination. Investigation of the UV-blocking capacity using different in vitro techniques revealed that the SLN dispersions produced in this study are at least twice as effective as their reference emulsions (conventional emulsions with identical lipid content). Placebo SLN even show greater UV-blocking efficacy than emulsions containing tocopherol acetate as the molecular sunscreen. Incorporation of tocopherol acetate into SLN leads to an overadditive UV-blocking effect. Furthermore, film formation of SLN on the skin and occlusivity were examined. The obtained data show that incorporation of tocopherol acetate into SLN leads to an improved sunscreen and skin care formulation.

Solid lipid nanoparticles (SLN)--a novel carrier for UV blockers.

Abstract: The formulation of safe sunscreen products is of high importance due to their increasing use because of the diminishing ozone layer. Solid lipid nanoparticles (SLN) are introduced as the new generation of carriers for cosmetics, especially for UV blockers for the use on human skin and/or hair and production thereof is described. The crystalline cetylpalmitate SLN particles have the ability of reflecting and scattering UV radiation on their own thus leading to photoprotection without the need for molecular sunscreens. An in vitro assay showed that a placebo cetyl palmitate SLN formulation is twice to three times as potent in absorbing UV radiation as a conventional emulsion. Incorporation of sunscreens into SLN lead to a synergistic photoprotection, i.e. higher than the additive effect of UV scattering caused by the SLN and UV absorption by the sunscreen. The photoprotective effect after incorporation of the molecular sunscreen 2-hydroxy-4-methoxybenzophenone (Eusolex 4360) into the SLN dispersion was observed to be increased threefold compared to a reference emulsion. Further, film formation on the skin was investigated by scanning electron microscopy, showing particle fusion due to water evaporation and formation of a dense film.

Incorporation of the model drug ubidecarenone into solid lipid nanoparticles.

Abstract: Purpose. The impact of drug incorporation on melt-homogenized tripalmitin nanoparticles is investigated with ubidecarenone as a model drug. The dispersions are studied with respect to their drug loading capacity, localization and physical state of the drug as well as to potential changes of the nanoparticle properties due to interactions between drug and triglyceride matrix. Methods. The investigations were carried out using photon correlation spectroscopy, differential scanning calorimetry, synchrotron radiation X-ray diffraction, ultracentrifugation, and cryo- and freeze-fracture transmission electron microscopy. Results. Ubidecarenone can be incorporated into the dispersions in concentrations higher than 50% of the dispersed phase. The drug is associated with the nanoparticles such that small drug amounts are bound tightly to the carrier matrix while excess drug adheres as a liquid phase to the crystalline particles. Drug incorporation lowers the crystallization and melting temperature of the particle matrix and accelerates the transition of the triglyceride into the stable β-polymorph after crystallization. Conclusions. Drug incorporation may significantly alter important physicochemical parameters of solid lipid nanoparticles. Slow release of ubidecarenone may only be possible for the fraction of drug which is tightly bound to the matrix while the liquid fraction should be rapidly released.

Scaling up feasibility of the production of solid lipid nanoparticles (SLN).

Abstract: Solid lipid nanoparticles (SLN/Lipopearls) are widely discussed as colloidal drug carrier system. In contrast to polymeric systems, such as polylactic copolyol capsules, these systems show up with a good biocompatibility, if applied parenterally. The solid lipid matrices can be comprised of fats or waxes and allow protection of incorporated active ingredients against chemical and physical degradation. The SLN can either be produced by "hot homogenisation" of melted lipids at elevated temperatures or a "cold homogenization" process. This paper deals with production technologies for SLN formulations, based on non-ethoxylated fat components for topical application and high pressure homogenization (APV Deutschland GmbH, D-Lubeck). Based on the chosen fat components, a novel and easy manufacturing and scaling up method was developed to maintain chemical and physical integrity of encapsulated active and carrier.

Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles.

Abstract: Modification of the dissolution rate and, thus, the enhancement of the bioavailability of a dopaminergic drug, piribedil, which has a low aqueous solubility and short elimination half-life have been the aim in this study. Preparations of micron and submicron particles using solid lipid carriers have been performed for this purpose. For the avoidance of solvent residues resulting from the preparation technique, cold and hot homogenization methods have been used to prepare solid lipid particles. After obtaining an appropriate particle size, piribedil loading and preparation yield by the use of those two methods, various formulations have been prepared with different lipid, drug and surfactant materials. The factors mentioned were found to affect properties of the particles, and the release rate was found to be the fastest in acidic medium. Suspensions of pure piribedil and a formulation, selected according to the results obtained from in vitro dissolution and particle size experiments, were compared using t...

Novel Lipid-Based Colloidal Dispersions as Potential Drug Administration Systems. Expectations and Reality

Abstract: Colloidal drug carriers offer a number of potential advantages as delivery systems for, for example, poorly soluble compounds. The first generation of colloidal carriers, in particular liposomes and sub-micron-sized lipid emulsions, are, however, associated with several drawbacks which so far have prevented the extensive use of these carriers in drug delivery. As an alternative colloidal delivery system melt-emulsified nanoparticles based on solid lipids have been proposed. Careful physicochemical characterization has demonstrated that these lipid-based nanosuspensions (solid lipid nanoparticles) are not just “emulsions with solidified droplets”. During the development process of these systems interesting phenomena have been observed, such as gel formation on solidification and upon storage, unexpected dynamics of polymorphic transitions, extensive annealing of nanocrystals over significant periods of time, stepwise melting of particle fractions in the lower-nanometer-size range, drug expulsion from the carrier particles on crystallization and upon storage, and extensive supercooling. These phenomena can be related to the crystalline nature of the carrier matrix in combination with its colloidal state. Observation of the supercooling effect has led to the development of a second new type of carrier system: nanospheres of supercooled melts. This novel type of colloidal lipidic carrier represents an intermediate state between emulsions and suspensions. Moreover, these dispersions are particularly suited to the study of the basic differences between colloidal triglyceride emulsions and suspensions. For many decades drug carriers have represented the only group of colloidal drug administration systems. Nowadays a fundamentally different group of dispersions is also under investigation: drug nanodispersions. They overcome a number of carrier-related drawbacks, such as limitations in drug load as well as side effects due to the matrix material of the carrier particles. Utilizing this concept virtually insoluble drugs can be formulated as colloidal particles, of solid or supercooled nature. For example, coenzyme Q10 (Q10) has been successfully processed into a dispersion of a supercooled melt. Droplet sizes in the lower nanometer range and shelf lives of more than 3 years can easily be achieved for Q10 dispersions. The drug load of the emulsion particles reaches nearly 100%.